Associated Papers
Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma.
Zhou Y et al.
Nature Communications, 2026
Rare cases in two Chinese MEN2A families with RET C634Y germline mutation-a homozygous female patient and heterozygous identical twins: a systematic review of literature.
Qi XP et al.
Frontiers in Endocrinology, 2026
Landscape of Phenotype-Genotype Correlations in Romanian Patients with Medullary Thyroid Carcinoma.
Stanescu LS et al.
Cancers, 2025
RET Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update.
Ricciardi Tenore C et al.
Genes, 2025
Discovery of a Proteolysis Targeting Chimera for TRKA and RET-derived oncoproteins.
Moccia M et al.
Scientific Reports, 2025
Geospatial inheritance across the breath of the RET mutational landscape of multiple endocrine neoplasia 2A.
Machens A et al.
Endocrine, 2025
Do Prognostic Differences Exist Among High-Risk RET Mutations? A Comparison of Outcomes Between the RET C634R and Other C634 Mutations in Hereditary Medullary Thyroid Carcinoma.
Zhang J et al.
Thyroid : Official Journal of the American Thyroid Association, 2025
Proposed framework for triage of putative germline variants detected via tumour genomic testing in UK oncology practice.
McVeigh TP et al.
Journal of Medical Genetics, 2025
Discovery of APS03118, a Potent and Selective Next-Generation RET Inhibitor with a Novel Kinase Hinge Scaffold.
Zhong J et al.
Journal of Medicinal Chemistry, 2025
Discovery of an orally bioavailable, CNS active pan-mutant RET kinase heterobifunctional degrader.
Orsi DL et al.
Rsc Medicinal Chemistry, 2025
Targeting RET in medullary thyroid cancer.
Newbold K et al.
Endocrine-related Cancer, 2025
Activating RET Mutations Promotes Osteoblastic Bone Metastases in Medullary Thyroid Cancer.
Bagheri-Yarmand R et al.
Biorxiv : the Preprint Server for Biology, 2025
Genomic testing for RET in the clinic: UK and global perspective.
Izatt L
Endocrine-related Cancer, 2025
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.
Katayama Y et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Treatment of non-small cell lung cancer with RET rearrangements.
Hoe HJ et al.
Cancer, 2025
Thyroid C-Cell Biology and Oncogenic Transformation.
Bagheri-Yarmand R et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer, 2025
Molecular profiling of sporadic medullary thyroid carcinomas - a next-generation sequencing-based study.
Altinay S et al.
Polish Journal of Pathology : Official Journal of the Polish Society of Pathologists, 2025
A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer.
Alqahtani T et al.
Bmc Cancer, 2024
Genetic landscape of Romanian PPGLs.
Lider-Burciulescu SM et al.
Journal of Cellular and Molecular Medicine, 2024
DLK1 Is Associated with Stemness Phenotype in Medullary Thyroid Carcinoma Cell Lines.
da Silva DD et al.
International Journal of Molecular Sciences, 2024
First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors.
Li W et al.
Signal Transduction and Targeted Therapy, 2024
Germline Mutations and Phenotypic Associations in Korean Patients With Pheochromocytoma and Paraganglioma: A Multicenter Study and Literature Review.
Jo KH et al.
Annals of Laboratory Medicine, 2024
Endocrine Perspective of Cutaneous Lichen Amyloidosis: RET-C634 Pathogenic Variant in Multiple Endocrine Neoplasia Type 2.
Florescu AF et al.
Clinics and Practice, 2024
WES-based screening of 7,000 newborns: A pilot study in Russia.
Shubina J et al.
Hgg Advances, 2024
Thyroid Malignancy and Cutaneous Lichen Amyloidosis: Key Points Amid RET Pathogenic Variants in Medullary Thyroid Cancer/Multiple Endocrine Neoplasia Type 2 (MEN2).
Stanescu LS et al.
International Journal of Molecular Sciences, 2024
RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.
Chen MF et al.
Drugs, 2024
[30 years of prophylactic thyroidectomy for hereditary medullary thyroid cancer : A milestone in translational medicine].
Dralle H et al.
Chirurgie (heidelberg, Germany), 2024
BRAF and RET polymorphism association with thyroid cancer risk, a preliminary study from Khyber Pakhtunkhwa population.
Batool M et al.
Molecular Biology Reports, 2024
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
Wang ZX et al.
Journal of Medicinal Chemistry, 2024
Accelerated MEN2A in homozygous RET carriers in the context of consanguinity.
Machens A et al.
European Journal of Endocrinology, 2024
Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer.
Chen W et al.
Npj Precision Oncology, 2024
Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results.
Machens A et al.
Current Opinion in Oncology, 2024
RET splice site variants in medullary thyroid carcinoma.
Saeed-Vafa D et al.
Frontiers in Genetics, 2024
Unveiling new chapters in medullary thyroid carcinoma therapy: advances in molecular genetics and targeted treatment strategies.
Huai JX et al.
Frontiers in Endocrinology, 2024
Selective RET Inhibitors (SRIs) in Cancer: A Journey from Multi-Kinase Inhibitors to the Next Generation of SRIs.
Clark L et al.
Cancers, 2023
Mining cancer genomes for change-of-metabolic-function mutations.
Tu KJ et al.
Communications Biology, 2023
Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China.
Pu X et al.
Thoracic Cancer, 2023
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.
Sahakian N et al.
Cancers, 2023
Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.
Steen EA et al.
Biochemical Pharmacology, 2023
Pediatric head and neck manifestations associated with multiple endocrine neoplasia syndromes.
Jellins T et al.
International Journal of Pediatric Otorhinolaryngology, 2023
Genetic and clinical screening for hereditary primary hyperparathyroidism in a large Chinese cohort: a single-center study.
Song A et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research, 2023
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I et al.
Nature Cancer, 2023
Cytoplasmic HIF-2α as tissue biomarker to identify metastatic sympathetic paraganglioma.
Karakaya S et al.
Scientific Reports, 2023
Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.
Martins RS et al.
Journal of Personalized Medicine, 2023
Adefovir Dipivoxil as a Therapeutic Candidate for Medullary Thyroid Carcinoma: Targeting RET and STAT3 Proto-Oncogenes.
Alqahtani T et al.
Cancers, 2023
A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Pheochromocytoma and Paraganglioma.
Fuchs TL et al.
The American Journal of Surgical Pathology, 2023
Integrated proteogenomic characterization of medullary thyroid carcinoma.
Shi X et al.
Cell Discovery, 2022